Developer docs
API playgroundTry for free, no card

Search company profiles

Genomics

Full company profile

uuid0000kpt

Namestring
Genomics
Legal namestring
Genomics Ltd.
Websiteurl
genomicsplc.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Genomics plc is a UK-based TechBio company spun out of the University of Oxford in 2014 by four world-leading geneticists, including CEO Peter Donnelly and co-founder Gilean McVean. The company is headquartered in Oxford with a London flagship office, and operates with 101-250 employees. Its core technology is a proprietary genotype-phenotype database compiled from more than 45,000 genome-wide association studies (GWAS), which powers polygenic risk score-based disease prediction and, more recently, the Mystra AI platform for pharmaceutical drug target discovery and validation. The company describes this database as one of the largest in the world and uses it to claim that drug targets supported by human genetic evidence are 2.6 times more likely to succeed in clinical trials.

The company operates a multi-segment business model with subscription-recurring revenue across four primary customer groups. First, life sciences and pharmaceutical companies (Novo Nordisk, BioMarin, Vertex Pharmaceuticals, Biogen, Eisai, BridgeBio Pharma, Relation Therapeutics, and Greywolf Therapeutics) access the Mystra AI platform for drug target identification, biomarker discovery, and clinical trial optimization. Second, healthcare systems — notably the NHS in the UK, alongside a US-facing Health Insights USA product — deploy genomic risk prediction and stratification tools for precision health delivery. Third, insurance partners use polygenic risk scores for underwriting. Fourth, employers offer the platform as a workforce wellness benefit, and individual consumers can access at-home DNA testing via a self-serve website. Distribution runs through direct enterprise field sales for pharma and healthcare deals, and a self-serve digital platform for consumers, employers, and insurance.

Genomics is privately held and has raised approximately $135 million across multiple funding rounds, with the largest being a $44.6M Series 3 in January 2024 led by Foresite Capital and F-Prime Capital, alongside investors including Oxford Science Enterprises, IP Group, Lansdowne Partners, Vertex Pharmaceuticals, and Innovate UK. The company was recognized in the Sunday Times 100 Tech list and received endorsement from the UK Health Minister as a 'jewel in our crown' for national health innovation following the 2026 London flagship opening.

Short descriptiontext

Genomics plc is an Oxford-based TechBio company that uses a proprietary database of 45,000+ GWAS studies and its Mystra AI platform to provide polygenic risk scores and drug target discovery services to pharmaceutical companies, healthcare systems including the NHS, insurers, employers, and individual consumers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersOxford, United Kingdom
HQ citystring
Oxford
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
genomic data platform, polygenic risk scores, drug target discovery, precision health analytics, human genetics AI
Industry3 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAANAL
Population Genomics & Preventive Precision Health Programs
SECONDARYHLAAANAA
Genomic Profiling & Sequencing-Based Precision Medicine
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Genomic Data Analytics Platform
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Life Sciences / Pharma Partnerships
TypeSubscription Recurring
Description

Revenue generated from partnerships with pharmaceutical companies for drug target discovery, biomarker identification, and clinical trial optimization using the company's genetic data platform and Mystra AI.

genomics.com
2Healthcare and NHS Services
TypeSubscription Recurring
Description

Revenue from precision health delivery through genomic risk prediction and stratification tools sold to healthcare systems and providers.

genomics.com
3Insurance/Employer Wellness Programs
TypeSubscription Recurring
Description

Revenue from predictive genomics services that transform underwriting for insurance partners and provide personalized health insights to employees for employer wellness programs.

genomics.com
4Mystra AI Platform Licensing
TypeSubscription Recurring
Description

Conversational AI platform licensed to pharmaceutical organizations to support drug target discovery and validation using human genetics data.

marketscreener.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B and B2C
B2B and B2C
Offering typeSoftware
Software
Brand1 record
1Mystra
Description

A conversational AI platform designed to accelerate drug target discovery and validation using large-scale human genetics data; launched as a separate brand with its own website at mystra.com

genomics.com
Core offering1 text field

Genomics operates an AI-powered human genetics platform built on one of the world's largest genotype-phenotype databases (45,000+ GWAS) that delivers polygenic risk scores for absolute disease risk prediction and powers the Mystra AI conversational agentic platform for drug target discovery and validation. Its offerings span pharma/biotech drug discovery partnerships, healthcare system precision health delivery (e.g., NHS), insurance underwriting genomics, employer wellness programs, and at-home DNA testing for consumers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Drug targets supported by human genetic evidence are 2.6x more likely to succeed in clinical trials
+2 more records
Product overview1 text field

Genomics offers a unified platform centered on genetic risk prediction and the Mystra AI platform for drug discovery. The core Genomics Platform provides disease risk assessment through polygenic risk scores powered by one of the world's largest genetic databases. The portfolio includes specialized solutions for different market segments: Health Insights UK/USA for healthcare systems, Solutions for Partners (insurance underwriting), Solutions for Employers (workplace wellness), Solutions for Healthcare (precision medicine delivery), and Solutions for Life Sciences (pharma/biotech research). The Mystra AI platform, launched in 2025-2026, represents the company's AI-powered offering for pharmaceutical drug target discovery and validation using human genetics data.

Product and service8 records
1Genomics Platform
CategoryCore platform
Description

The company's primary platform powered by one of the world's largest genetic databases, providing disease risk prediction through polygenic risk scores and DNA analysis for healthcare providers, insurers, employers, and life sciences companies.

2Mystra AI Platform
CategoryAI platform for drug discovery
Description

A conversational agentic AI platform designed to accelerate drug target discovery and validation using large-scale human genetics data from the world's largest genotype-phenotype database, adopted by Novo Nordisk, BridgeBio Pharma, and Relation Therapeutics.

3Solutions for Life Sciences
CategoryPharma/Biotech solutions
Description

Pharmaceutical research solutions for drug discovery acceleration, clinical trial design optimization, biomarker identification, and post-market studies to help pharma and biotech companies deliver more targeted therapeutics.

4Solutions for Healthcare
CategoryHealthcare provider solutions
Description

Genetic risk prediction and stratification tools enabling healthcare providers to deliver precision health from individuals to populations, including disease prevention and population health management.

5Health Insights UK
CategoryHealthcare system solutions
Description

Genomic risk prediction and stratification solution for the UK healthcare system enabling precision health delivery through polygenic risk scores.

6Health Insights USA
CategoryHealthcare system solutions
Description

Genomic health insights solution for the US market delivering precision health through genetic risk prediction and polygenic risk scores.

7Solutions for Partners
CategoryInsurance underwriting solutions
Description

Predictive genomics solutions for insurance partners, using advanced polygenic risk scores and data science to predict individual disease risk from a single at-home DNA test, transforming underwriting accuracy and policyholder engagement.

8Solutions for Employers
CategoryEmployer wellness solutions
Description

Employee health engagement platform providing personalised health tools and guidance based on polygenic risk scores to improve employee wellbeing and quality of life.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-29
Description

Genomics entered a strategic partnership with clinical-stage biotech Greywolf Therapeutics to analyze large-scale genetic datasets evaluating how ERAP (Endoplasmic Reticulum Aminopeptidase) enzyme variants influence autoimmune disease risk across multiple conditions. The insights guide Greywolf's indication selection and pipeline development, including its Phase 1/2 trial for axial spondyloarthritis and expansion into inflammatory bowel disease and psoriasis. The collaboration leverages Genomics' proprietary genotype-phenotype data resource.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Genomics and BioMarin collaborated on research analyzing global biobank data for three ultra-rare lysosomal storage disorders (MPS IVA, MPS VI, and CLN2 disease). The research identified geographic regions with high underdiagnosis rates to support earlier genetic diagnosis and expand treatment access. This was presented at the ACMG Clinical Genetics Meeting 2026.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Tempus Labs
TypeBroad incumbent
Description

AI-powered precision medicine platform integrating clinical and molecular data for oncology and beyond. Comparable as a broader incumbent selling AI/data infrastructure into pharma and providers.

TypeDirect peer
Description

Amgen-owned human genetics research company that pioneered population-scale genotype-phenotype research for drug target discovery. Closely comparable to Genomics' core data asset and pharma business model.

TypeDirect peer
Description

Large-scale human genetics platform within Regeneron, sequencing hundreds of thousands of exomes to power drug discovery. Directly comparable in mission and use of population genetics for pharma R&D.

TypeDirect peer
Description

AI/ML-driven drug discovery company combining machine learning with biology to identify novel targets and predict therapeutic outcomes. Comparable to Genomics' Mystra AI positioning for pharma target discovery.

TypeDirect peer
Description

TechBio company combining high-throughput biology, automation, and AI to discover new medicines at scale. Competes with Genomics for pharma AI-drug-discovery budgets and partnerships.

TypeDirect peer
Description

UK-based AI drug discovery company applying machine learning to biomedical knowledge graphs for target identification. A direct peer in AI-enabled pharma target discovery, with geographic overlap.

TypeEmerging player
Description

AI-for-health company building federated learning models on patient data for drug discovery and precision medicine. Overlaps with Genomics on pharma AI partnerships and translational data strategy.

TypeEmerging player
Description

Precision health platform combining whole-genome sequencing, AI, and clinical data for disease risk prediction. Comparable to Genomics' polygenic risk score and precision health offering for consumers and providers.

TypeEmerging player
Description

Consumer genetic testing company with a therapeutics arm leveraging genetic data for drug discovery. Overlaps with Genomics on consumer polygenic health and pharma genetic-evidence licensing.

TypeBroad incumbent
Description

Dominant DNA sequencing technology and instruments provider with growing downstream informatics and population genomics initiatives. Relevant incumbent across the genomics stack that Genomics sits upon.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Genomics

Genomic Data Analytics Platformgenomicsplc.com

Genomics plc is an Oxford-based TechBio company that uses a proprietary database of 45,000+ GWAS studies and its Mystra AI platform to provide polygenic risk scores and drug target discovery services to pharmaceutical companies, healthcare systems including the NHS, insurers, employers, and individual consumers.

What Genomics does

Genomics plc is a UK-based TechBio company spun out of the University of Oxford in 2014 by four world-leading geneticists, including CEO Peter Donnelly and co-founder Gilean McVean. The company is headquartered in Oxford with a London flagship office, and operates with 101-250 employees. Its core technology is a proprietary genotype-phenotype database compiled from more than 45,000 genome-wide association studies (GWAS), which powers polygenic risk score-based disease prediction and, more recently, the Mystra AI platform for pharmaceutical drug target discovery and validation. The company describes this database as one of the largest in the world and uses it to claim that drug targets supported by human genetic evidence are 2.6 times more likely to succeed in clinical trials.

The company operates a multi-segment business model with subscription-recurring revenue across four primary customer groups. First, life sciences and pharmaceutical companies (Novo Nordisk, BioMarin, Vertex Pharmaceuticals, Biogen, Eisai, BridgeBio Pharma, Relation Therapeutics, and Greywolf Therapeutics) access the Mystra AI platform for drug target identification, biomarker discovery, and clinical trial optimization. Second, healthcare systems — notably the NHS in the UK, alongside a US-facing Health Insights USA product — deploy genomic risk prediction and stratification tools for precision health delivery. Third, insurance partners use polygenic risk scores for underwriting. Fourth, employers offer the platform as a workforce wellness benefit, and individual consumers can access at-home DNA testing via a self-serve website. Distribution runs through direct enterprise field sales for pharma and healthcare deals, and a self-serve digital platform for consumers, employers, and insurance.

Genomics is privately held and has raised approximately $135 million across multiple funding rounds, with the largest being a $44.6M Series 3 in January 2024 led by Foresite Capital and F-Prime Capital, alongside investors including Oxford Science Enterprises, IP Group, Lansdowne Partners, Vertex Pharmaceuticals, and Innovate UK. The company was recognized in the Sunday Times 100 Tech list and received endorsement from the UK Health Minister as a 'jewel in our crown' for national health innovation following the 2026 London flagship opening.

Genomics firmographics

Firmographics
Name
Genomics
Legal name
Genomics Ltd.
Website
https://genomicsplc.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
101–250 employees
Short description
Genomics plc is an Oxford-based TechBio company that uses a proprietary database of 45,000+ GWAS studies and its Mystra AI platform to provide polygenic risk scores and drug target discovery services to pharmaceutical companies, healthcare systems including the NHS, insurers, employers, and individual consumers.
Ownership category
akta.pro rank

Genomics industry classification

Industry
Product category
Genomic Data Analytics Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAANAL
Population Genomics & Preventive Precision Health Programs
SECONDARYHLAAANAA
Genomic Profiling & Sequencing-Based Precision Medicine

Keywords

  • Genomic data platform
  • Polygenic risk scores
  • Drug target discovery
  • Precision health analytics
  • Human genetics AI

Where Genomics is headquartered

Location

Headquarters

HQ city
Oxford
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Genomics business model

Business model
GTM type
B2B and B2C
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Life Sciences / Pharma Partnerships: Revenue generated from partnerships with pharmaceutical companies for drug target discovery, biomarker identification, and clinical trial optimization using the company's genetic data platform and Mystra AI.
  2. Healthcare and NHS Services: Revenue from precision health delivery through genomic risk prediction and stratification tools sold to healthcare systems and providers.
  3. Insurance/Employer Wellness Programs: Revenue from predictive genomics services that transform underwriting for insurance partners and provide personalized health insights to employees for employer wellness programs.
  4. Mystra AI Platform Licensing: Conversational AI platform licensed to pharmaceutical organizations to support drug target discovery and validation using human genetics data.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Genomics product offering

Product offering

Core offering

Genomics operates an AI-powered human genetics platform built on one of the world's largest genotype-phenotype databases (45,000+ GWAS) that delivers polygenic risk scores for absolute disease risk prediction and powers the Mystra AI conversational agentic platform for drug target discovery and validation. Its offerings span pharma/biotech drug discovery partnerships, healthcare system precision health delivery (e.g., NHS), insurance underwriting genomics, employer wellness programs, and at-home DNA testing for consumers.

Product overview

Genomics offers a unified platform centered on genetic risk prediction and the Mystra AI platform for drug discovery. The core Genomics Platform provides disease risk assessment through polygenic risk scores powered by one of the world's largest genetic databases. The portfolio includes specialized solutions for different market segments: Health Insights UK/USA for healthcare systems, Solutions for Partners (insurance underwriting), Solutions for Employers (workplace wellness), Solutions for Healthcare (precision medicine delivery), and Solutions for Life Sciences (pharma/biotech research). The Mystra AI platform, launched in 2025-2026, represents the company's AI-powered offering for pharmaceutical drug target discovery and validation using human genetics data.

Differentiator

Problem solved

Functional benefit

Brands

  • Mystra: A conversational AI platform designed to accelerate drug target discovery and validation using large-scale human genetics data; launched as a separate brand with its own website at mystra.com

Products and services

  • Genomics Platform The company's primary platform powered by one of the world's largest genetic databases, providing disease risk prediction through polygenic risk scores and DNA analysis for healthcare providers, insurers, employers, and life sciences companies.
  • Mystra AI Platform A conversational agentic AI platform designed to accelerate drug target discovery and validation using large-scale human genetics data from the world's largest genotype-phenotype database, adopted by Novo Nordisk, BridgeBio Pharma, and Relation Therapeutics.
  • Solutions for Life Sciences Pharmaceutical research solutions for drug discovery acceleration, clinical trial design optimization, biomarker identification, and post-market studies to help pharma and biotech companies deliver more targeted therapeutics.
  • Solutions for Healthcare Genetic risk prediction and stratification tools enabling healthcare providers to deliver precision health from individuals to populations, including disease prevention and population health management.
  • Health Insights UK Genomic risk prediction and stratification solution for the UK healthcare system enabling precision health delivery through polygenic risk scores.
  • Health Insights USA Genomic health insights solution for the US market delivering precision health through genetic risk prediction and polygenic risk scores.
  • Solutions for Partners Predictive genomics solutions for insurance partners, using advanced polygenic risk scores and data science to predict individual disease risk from a single at-home DNA test, transforming underwriting accuracy and policyholder engagement.
  • Solutions for Employers Employee health engagement platform providing personalised health tools and guidance based on polygenic risk scores to improve employee wellbeing and quality of life.

Quantifiable outcome

  • Drug targets supported by human genetic evidence are 2.6x more likely to succeed in clinical trials
  • +2 more outcomes

Companies that use Genomics

Customer profile

Named customers8 records

Segments5 records

Ideal customer profiles5 records

Genomics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature3 records

Genomics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Greywolf TherapeuticscoreStrategic or Co-development Partner · 29 April 2026Genomics entered a strategic partnership with clinical-stage biotech Greywolf Therapeutics to analyze large-scale genetic datasets evaluating how ERAP (Endoplasmic Reticulum Aminopeptidase) enzyme variants influence autoimmune disease risk across multiple conditions. The insights guide Greywolf's indication selection and pipeline development, including its Phase 1/2 trial for axial spondyloarthritis and expansion into inflammatory bowel disease and psoriasis. The collaboration leverages Genomics' proprietary genotype-phenotype data resource.
  • BioMarin Pharmaceutical Inc.coreStrategic or Co-development PartnerGenomics and BioMarin collaborated on research analyzing global biobank data for three ultra-rare lysosomal storage disorders (MPS IVA, MPS VI, and CLN2 disease). The research identified geographic regions with high underdiagnosis rates to support earlier genetic diagnosis and expand treatment access. This was presented at the ACMG Clinical Genetics Meeting 2026.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Genomics competitors and assessment

Company assessment

Broad incumbents

  • Tempus Labs: AI-powered precision medicine platform integrating clinical and molecular data for oncology and beyond. Comparable as a broader incumbent selling AI/data infrastructure into pharma and providers.
  • Illumina: Dominant DNA sequencing technology and instruments provider with growing downstream informatics and population genomics initiatives. Relevant incumbent across the genomics stack that Genomics sits upon.

Direct peers

  • deCODE genetics: Amgen-owned human genetics research company that pioneered population-scale genotype-phenotype research for drug target discovery. Closely comparable to Genomics' core data asset and pharma business model.
  • Regeneron Genetics Center: Large-scale human genetics platform within Regeneron, sequencing hundreds of thousands of exomes to power drug discovery. Directly comparable in mission and use of population genetics for pharma R&D.
  • Insitro: AI/ML-driven drug discovery company combining machine learning with biology to identify novel targets and predict therapeutic outcomes. Comparable to Genomics' Mystra AI positioning for pharma target discovery.
  • Recursion Pharmaceuticals: TechBio company combining high-throughput biology, automation, and AI to discover new medicines at scale. Competes with Genomics for pharma AI-drug-discovery budgets and partnerships.
  • BenevolentAI: UK-based AI drug discovery company applying machine learning to biomedical knowledge graphs for target identification. A direct peer in AI-enabled pharma target discovery, with geographic overlap.

Emerging players

  • Owkin: AI-for-health company building federated learning models on patient data for drug discovery and precision medicine. Overlaps with Genomics on pharma AI partnerships and translational data strategy.
  • Human Longevity Inc. Precision health platform combining whole-genome sequencing, AI, and clinical data for disease risk prediction. Comparable to Genomics' polygenic risk score and precision health offering for consumers and providers.
  • 23andMe: Consumer genetic testing company with a therapeutics arm leveraging genetic data for drug discovery. Overlaps with Genomics on consumer polygenic health and pharma genetic-evidence licensing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Genomics social profiles

Digital presence

Genomics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Genomics leadership team

Management profile

Number of profiles

Profiles3 records

Genomics funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Genomics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genomics

What does Genomics do?

Genomics operates an AI-powered human genetics platform built on one of the world's largest genotype-phenotype databases (45,000+ GWAS) that delivers polygenic risk scores for absolute disease risk prediction and powers the Mystra AI conversational agentic platform for drug target discovery and validation. Its offerings span pharma/biotech drug discovery partnerships, healthcare system precision health delivery (e.g., NHS), insurance underwriting genomics, employer wellness programs, and at-home DNA testing for consumers.

Is Genomics a public or private company?

Genomics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Genomics founded?

Genomics was founded in 2014. It employs 101 to 250 people.

Where is Genomics based?

Genomics is headquartered in Oxford, United Kingdom, in the Europe region.

How does Genomics make money?

Four revenue lines are on record. Life Sciences / Pharma Partnerships are the primary driver. The others are healthcare and NHS Services, insurance/Employer Wellness Programs and mystra AI Platform Licensing.

Who are Genomics's main competitors?

Broad incumbents on record are Tempus Labs and Illumina. Direct peers are deCODE genetics, Regeneron Genetics Center, Insitro, Recursion Pharmaceuticals and BenevolentAI. Emerging players are Owkin, Human Longevity Inc. and 23andMe.

Does Genomics have an API?

No public API is recorded for Genomics.

What industry is Genomics in?

Genomics's product category is Genomic Data Analytics Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAANAL, Population Genomics & Preventive Precision Health Programs. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PMLiVEGenomics extends drug discovery collaboration with VertexGenomics extended its four-year drug target discovery and validation collaboration with Vertex Pharmaceuticals, building on an eight-year partnership. The extension's total potential contract value exceeds $220m, with tiered royalties on future net sales.MoomooGenomics Ltd. Announces Extension of Strategic Drug Discovery Collaboration With Vertex PharmaceuticalsGenomics extended its drug target discovery collaboration with Vertex Pharmaceuticals for four years, building on an eight-year partnership that began in 2018. The extension carries a potential contract value exceeding $220 million, with tiered royalties on future net sales.YahooGenomics Ltd. Announces Extension of Strategic Drug Discovery Collaboration with Vertex PharmaceuticalsGenomics extended its drug target discovery collaboration with Vertex Pharmaceuticals for four years, building on an eight-year partnership. The total potential contract value exceeds $220 million, with tiered royalties on future net sales. The companies will continue using human genetics to identify drug targets and biomarkers.PR NewswireGenomics Ltd. Announces Extension of Strategic Drug Discovery Collaboration with Vertex PharmaceuticalsGenomics extended its drug target discovery collaboration with Vertex Pharmaceuticals for four years, building on an eight-year partnership that began in 2018. The extension carries a potential contract value exceeding $220 million, with tiered royalties on future net sales.BioSpaceArtificial Intelligence (AI) in Biotechnology Market Size to Exceed USD 31.87 Billion by 2035 Rising Demand for Faster Drug Discovery and Precision MedicineThe global AI in biotechnology market is projected to reach USD 31.87 billion by 2035, up from USD 6.68 billion in 2026, growing at a CAGR of 18.99%. North America held the largest share in 2025, while Asia Pacific is expected to grow fastest. Growth is driven by demand for rapid drug discovery and precision medicine.The UK's technology trade associationThe Genetics Revolution, Made Real: Professor Sir Peter Donnelly, GenomicsProfessor Sir Peter Donnelly, CEO of Genomics, has built a company to turn genomic risk prediction into population-scale preventive healthcare. His work includes UK's first MHRA-registered polygenic risk score products and a clinical trial in NHS primary care. The NHS has committed to rolling out PRS technology by 2035.Digital Health NewsGenomics Launches Mystra AI Platform to Accelerate Drug Target Discovery Using Human Genetics DataGenomics, a London-based techbio company, has launched Mystra AI, a conversational AI platform designed to support drug target discovery and validation using large-scale human genetics data. The platform leverages what Genomics describes as the world's largest genotype-phenotype database, compiled from more than 45,000 genome-wide association studies, and is already being used by major pharmaceutical organizations including Novo Nordisk, BridgeBio Pharma, and Relation Therapeutics. According to the company, drug targets supported by human genetic evidence are 2.6 times more likely to succeed in clinical trials, where approximately 95% of candidates currently fail.MarketScreenerIP : Genomics launches the Mystra AI platform, adopted by industry giants and up-and-coming biotechsGenomics, a science-led TechBio company spun out of the University of Oxford in 2014, announced the launch of Mystra AI, a conversational agentic AI platform designed to accelerate drug target discovery and validation by leveraging what the company describes as the world's largest and most diverse human genotype-phenotype database.PR NewswireGenomics Launches the Mystra AI Platform, Adopted by Industry Giants and Up-and-Coming BiotechsGenomics, a UK-based Techbio company spun out of the University of Oxford in 2014, announced on June 2, 2026 the launch of Mystra AI, a conversational AI platform built on its largest human genotype-phenotype database to aid drug target discovery and validation. The company cites a 95% clinical trial failure rate and states targets with genetic support are 2.6 times more likely to succeed. Partners include Amazon Web Services, Novo Nordisk, BridgeBio Pharma and Relation Therapeutics.PR NewswireGenomics Launches the Mystra AI Platform, Adopted by Industry Giants and Up-and-Coming BiotechsGenomics launched the Mystra AI platform in London, a human genetics agentic AI designed to enhance drug target discovery and validation by leveraging the world's largest genotype-phenotype database. The platform aims to address the high failure rate in drug development, which costs over $2.3 billion per project, by improving clinical trial success using genetic insights.